UCB expands in Brazil
- Details
- Category: UCB
UCB (Euronext Brussels: UCB) and Meizler Biopharma, a privately-owned Brazilian pharmaceutical company, have signed an agreement by which UCB acquires 51% of Meizler Biopharma. The agreement foresees performance related milestone payments in the coming years as well as an option to purchase the remaining 49% later in time.
Genzyme recognizes World MS Day
- Details
- Category: Genzyme
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), marked World MS Day with activities across its global network and new programs designed to mobilize and inspire people living with multiple sclerosis.
Bristol-Myers Squibb announces global collaboration with leading academic institutions
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology.
Lundbeck's Lu AE58054 meets primary endpoint
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announced that Lu AE58054 has met its primary endpoint in a fixed dose, randomized, placebo-controlled clinical study in 278 patients suffering from Alzheimer's disease.
Innovative public-private collaboration launches to tackle antibiotic research
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics.
Bayer's Regorafenib submitted for EU and US marketing authorization
- Details
- Category: Bayer
Bayer HealthCare has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) and a New Drug Application to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (mCRC).
One million signatures needed to call upon World Health Organisation
- Details
- Category: Boehringer Ingelheim
The 1 Mission 1 Million - Getting to the Heart of Stroke initiative is launching a petition to call upon the World Health Organisation, its member states and health authorities worldwide to recognise atrial fibrillation as a risk factor for stroke and set clinical management targets that could save one million mothers, fathers, uncles, aunts and grandparents each year through better atrial fibrillation management, stroke prevention and education.
More Pharma News ...
- Roche will report new data on important progress for people with advanced cancers at ASCO 2012
- Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
- Merck total revenues increase 3.2% to € 2.6 billion
- Pfizer provides topline results from Phase 3 study of Torisel®
- GlaxoSmithKline to fully acquire Cellzome for £61 million
- Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India
- Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership